Acute Migraine Management in the Emergency Department for Triptan‑Intolerant Patients

1. Evidence‑Based Pharmacologic Recommendations

Intravenous prochlorperazine (10 mg) or metoclopramide (10–20 mg) with diphenhydramine (25–50 mg) should be used as first‑line therapy for acute migraine in patients who cannot receive triptans; these dopamine antagonists have high‑quality evidence demonstrating efficacy comparable to all other medication classes. 1
Intravenous dexketoprofen (≈50 mg) is a highly effective alternative when dopamine antagonists are contraindicated, supported by multiple Class I studies. 2
CGRP receptor antagonists (gepants) such as rimegepant, ubrogepant, or zavezepant may be employed as rescue therapy for patients who do not respond to or cannot tolerate combination therapy; evidence for emergency‑department use is limited. 1, 2
Dihydroergotamine (1 mg IV or intranasal) can be offered as a rescue option after failure of first‑line agents, but it shares cardiovascular contraindications with triptans and should be used cautiously. 2
Antiemetics (metoclopramide, prochlorperazine, or promethazine) should be added for severe nausea or vomiting, recognizing that metoclopramide and prochlorperazine also serve as primary migraine treatments. 1, 2

Opioids (e.g., hydromorphone, meperidine) must not be used for acute migraine in the ED because they are inferior to dopamine antagonists and NSAIDs and increase the risk of medication‑overuse headache. High‑quality evidence supports this recommendation. 1, 2
Butalbital‑containing products must not be offered; they have a low threshold for medication‑overuse headache (≥10 days/month) and lack supporting efficacy data. Evidence from a high‑quality source (Annals of Internal Medicine) underpins this contraindication. 1

Initial assessment must confirm triptan intolerance (adverse effects, contraindications, or inadequate response) and exclude cardiovascular contraindications before selecting alternative therapies. This is based on high‑quality evidence. 1
If first‑line dopamine antagonists fail within 30–60 minutes, rescue therapy should consist of DHE 1 mg IV or a gepant (if formulary permits). Evidence for this step is limited but documented. 2
At discharge, prescribe a dexamethasone taper to reduce headache recurrence (recurrence rates can exceed 50 % within 24–72 hours) and arrange outpatient access to gepants for future attacks. Evidence supporting discharge planning comes from high‑quality sources. 1, 2

Patients with cardiovascular disease should avoid triptans and DHE; CGRP antagonists are the preferred acute therapy because they lack vasoconstrictive effects. This recommendation is supported by high‑quality evidence. 1
During pregnancy and lactation, acetaminophen is the safest option, and NSAIDs may be used before the third trimester. This guidance is derived from a guideline source (Praxis Medical Insights). 3

Early administration of any effective agent improves response rates compared with delayed dosing; prompt treatment is essential. Evidence from a guideline source. 3
“Triptan intolerance” based on failure of a single triptan does not preclude response to another triptan; however, this consideration is more relevant to outpatient management than to ED rescue. Supported by high‑quality evidence. 1, 2